Real-world use of empaglifozin and dapaglifozin in patients with HEART failure

Back

HFA Premium Access

Real-world use of empaglifozin and dapaglifozin in patients with HEART failure

Session: Acute heart failure - pharmacotherapy 2

Topic: Pharmacotherapy

Speaker: Associate Professor B. MURAT (Eskisehir, TR)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Associate Professor Bektas MURAT

Eskisehir City Hospital, Eskisehir (Türkiye)

0 follower

6 more presentations in this session

The effect of statin persistence on prognosis in acute heart failure patients

Speaker: Associate Professor H. Kim (Guri, KR)

Acute diuretic effect of empagliflozin in de novo heart failure: a secondary analysis of the EMPAG-HF trial

Speaker: Doctor J. Bogoviku (Jena, DE)

Renal function in patients with acute decompensated de novo heart failure treated with the SGLT2 inhibitor empagliflozin: a secondary analysis of the EMPAG-HF trial

Speaker: Doctor J. Bogoviku (Jena, DE)

Acute effect of empagliflozin on echocardiographic parameter in de novo heart failure: a secondary analysis of the EMPAG-HF trial

Speaker: Doctor J. Bogoviku (Jena, DE)

Impact of af on sacubitril/valsartan dosing, persistance of treatment and associated outcomes in heart failure patients with reduced ejection fraction

Speaker: Doctor N. Bonini (Modena, IT)

Access the full session

Acute heart failure - pharmacotherapy 2

Speakers: Associate Professor B. MURAT, Associate Professor H. Kim, Doctor J. Bogoviku, Doctor J. Bogoviku, Doctor J. Bogoviku...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources